Crystalline Solid and Amorphous Forms of (-)-Halofenate and Methods Related Thereto
AssigneesDiaTex, Inc., Metabolex, Inc.
InventorsEdward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
Life of this patent
Estimating the term…
Loading patent…
AssigneesDiaTex, Inc., Metabolex, Inc.
InventorsEdward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
Estimating the term…
The present invention provides crystalline solid and amorphous forms of (−)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (−)-halofenate.
The compound (−)-halofenate in a crystalline solid form A characterized by at least one of:
The compound (−)-halofenate in a crystalline solid form A characterized by an infra red spectrum substantially in accordance with FIG. 3.
The compound (−)-halofenate in a crystalline solid form A characterized by a Raman spectrum substantially in accordance with FIG. 5.
The compound (−)-halofenate in a crystalline solid form A characterized by at least one of
The compound (−)-halofenate in a crystalline solid form A characterized by an X-ray powder diffraction pattern comprising peaks at about 10.8°2θ and about 22.0°2θ, and about 29.3°2θ.
The compound (−)-halofenate in a crystalline solid form A characterized by a DSC maximum endotherm at about 80° C.
The compound (−)-halofenate in a substantially pure crystalline solid form A characterized by at least one of:
The compound (−)-halofenate in a substantially pure crystalline solid form A characterized by an infra red spectrum substantially in accordance with FIG. 3.
The compound (−)-halofenate in a substantially pure crystalline solid form A characterized by a Raman spectrum substantially in accordance with FIG. 5.
The compound (−)-halofenate in a substantially pure crystalline solid form A characterized by at least one of
The compound (−)-halofenate in a substantially pure crystalline solid form A characterized by an X-ray powder diffraction pattern comprising peaks at about 10.8 °2θ about 22.0°2θ, and about 29.3°2θ.
The compound (−)-halofenate in a substantially pure crystalline solid form A characterized by a DSC maximum endotherm at about 80° C.
The compound (−)-halofenate in a crystalline solid form B characterized by at least one of:
The compound (−)-halofenate in a crystalline solid form B characterized by at least one of:
The compound (−)-halofenate in a crystalline solid form B characterized by an X-ray powder diffraction pattern comprising peaks at about 6.2°2θ and about 12.4°2θ.
The compound (−)-halofenate in a crystalline solid form B characterized by a DSC endotherm maximum of about 71° C.
The compound (−)-halofenate in a substantially pure crystalline solid form B characterized by at least one of:
The compound (−)-halofenate in a substantially pure crystalline solid form B characterized by at least one of:
The compound (−)-halofenate in a substantially pure crystalline solid form B characterized by an X-ray powder diffraction pattern comprising peaks at about 6.2 °2θ and about 12.4°2θ.
The compound (−)-halofenate in a substantially pure crystalline solid form B characterized by a DSC endotherm maximum of about 71° C.
The compound (−)-halofenate in a crystalline solid form C characterized by at least one of:
The compound (−)-halofenate in a crystalline solid form C characterized by an X-ray powder diffraction pattern comprising peaks at about 9.9°2θ and about 13.3°2θ.
The compound (−)-halofenate in a substantially pure crystalline solid form C characterized by at least one of:
The compound (−)-halofenate in a substantially pure crystalline solid form C characterized by an X-ray powder diffraction pattern comprising peaks at about 9.9 °2θ and about 13.3°2θ.
The compound (−)-halofenate in a crystalline solid form D characterized by at least one of:
The compound (−)-halofenate in a crystalline solid form D characterized by an infra red spectrum substantially in accordance with FIG. 20.
The compound (−)-halofenate in a crystalline solid form D characterized by a Raman spectrum substantially in accordance with FIG. 22.
The compound (−)-halofenate in a crystalline solid form D characterized by at least one of:
The compound (−)-halofenate in a crystalline solid form D characterized by an X-ray powder diffraction pattern comprising peaks at about 9.6°2θ and about 17.4°2θ.
The compound (−)-halofenate in a crystalline solid form D characterized by a DSC endotherm maximum at about 74° C.
The compound (−)-halofenate in a substantially pure crystalline solid form D characterized by at least one of:
The compound (−)-halofenate in a substantially pure crystalline solid form D characterized by an infra red spectrum substantially in accordance with FIG. 20.
The compound (−)-halofenate in a substantially pure crystalline solid form D characterized by a Raman spectrum substantially in accordance with FIG. 22.
The compound (−)-halofenate in a substantially pure crystalline solid form D characterized by at least one of:
The compound (−)-halofenate in a substantially pure crystalline solid form D characterized by an X-ray powder diffraction pattern comprising peaks at about 9.6 °2θ and about 17.4°2θ.
The compound (−)-halofenate in a substantially pure crystalline solid form D characterized by a DSC endotherm maximum at about 74° C.
The compound (−)-halofenate in a crystalline solid form E characterized by at least one of:
The compound (−)-halofenate in a crystalline solid form E characterized by a infra red spectrum substantially in accordance with FIG. 28.
The compound (−)-halofenate in a crystalline solid form E characterized by a Raman spectrum substantially in accordance with FIG. 30.
The compound (−)-halofenate in a crystalline solid form E characterized by at least one of:
The compound (−)-halofenate in a crystalline solid form E characterized by an X-ray powder diffraction pattern comprising peaks at about 11.8°2θ and about 13.0°2θ.
The compound (−)-halofenate in a substantially pure crystalline solid form E characterized by at least one of:
The compound (−)-halofenate in a substantially pure crystalline solid form E characterized by a infra red spectrum substantially in accordance with FIG. 28.
The compound (−)-halofenate in a substantially pure crystalline solid form E characterized by a Raman spectrum substantially in accordance with FIG. 30.
The compound (−)-halofenate in a substantially pure crystalline solid form E characterized by at least one of:
The compound (−)-halofenate in a substantially pure crystalline solid form E characterized by an X-ray powder diffraction pattern comprising peaks at about 11.8 °2θ and about 13.0°2θ.
The compound (−)-halofenate in an amorphous form.
The compound (−)-halofenate in a substantially pure amorphous form characterized by an X-ray powder diffraction pattern comprising a broad peak substantially between about 15 and about 30°2θ.
The compound (−)-halofenate in a substantially pure amorphous form characterized by an X-ray powder diffraction pattern substantially in accordance with FIG.
The compound (−)-halofenate in a form selected from the group consisting of crystalline solid form A, B, C, D, E and amorphous that is in an isolated form.
The compound according to any one of the preceding claims consisting of greater than 91% (−)-halofenate and less than 9% of chemical impurities other than (−)-halofenate based on the total weight of (−)-halofenate.
The compound according to any one of the preceding claims wherein at least 91% is in crystalline solid form A and less than 9% is in a form selected from the group consisting of B, C, D, E and amorphous based on the total weight of (−)-halofenate.
The compound according to any one of the preceding claims wherein at least 91% is the (−) isomer and less than 9% is the (+) isomer based on the total weight of halofenate.
A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of the preceding claims and a pharmaceutically acceptable vehicle or carrier.
A composition comprising at least one solid form of (−) halofenate wherein said solid form is selected from the group consisting of Form A, Form B, Form C, Form D, Form E, and the amorphous form.
A composition comprising at least two solid forms of (−) halofenate wherein each solid form is independently selected from the group consisting of Form A, Form B, Form C, Form D, and the amorphous form.
A pharmaceutical composition of (−) halofenate comprising Form A of (−) halofenate, a solid form of (−) halofenate selected from the group consisting of Form B, Form C, Form D, Form E, the amorphous form and combinations thereof;
A pharmaceutical composition comprising a therapeutically effective amount of (−) halofenate in crystalline solid Form A characterized by an X-ray powder diffraction pattern comprising peaks at about 10.8°2θ, about 22.0°2θ, about 29.3°2θ and a Raman spectrum comprising at least one peak selected from about 3087 cm−1 and about 1663 cm';
A pharmaceutical composition comprising a therapeutically effective amount of (−) halofenate in crystalline solid Form B characterized by an X-ray Powder diffraction pattern comprising peaks at about 6.2°2θ and about 12.4°2θ, and at least one peak selected from about 18.8°2θ, about 20.1θ2°, and about 14.0°2θ;
A pharmaceutical composition comprising a therapeutically effective amount of (−) halofenate in crystalline solid Form C characterized by an X-ray Powder diffraction pattern comprising peaks at about 9.9°2θ and about 13.3°2θ, and at least one peak selected from about 15.5°2θ, about 23.1°2θ, about 14.7°2θ, and about 25.9°2θ;
A pharmaceutical composition comprising a therapeutically effective amount of (−) halofenate in crystalline solid Form D characterized by an X-ray Powder diffraction pattern comprising peaks at about 9.6°2θ and about 17.4°2θ, and a Raman spectrum comprising at least one peak selected from about 3077 cm−1 and about 1329 cm−1;
A pharmaceutical composition comprising a therapeutically effective amount of (−) halofenate in crystalline solid Form E characterized by an X-ray Powder diffraction pattern comprising peaks at about 11.8°2θ and about 13.0°2θ and a Raman spectrum comprising at least one peak selected from about 2969 cm−1, about 1746 cm−1, and about 1657 cm−1;
A pharmaceutical composition comprising a therapeutically effective amount of (−) halofenate in an amorphous form characterized by a broad peak between about 15°2θ and about 30°2θ;
The compound of (−) halofenate in a crystalline solid Form A characterized by an X-ray Powder diffraction pattern comprising a peak at about 10.8°2θ and an infrared spectrum comprising at least one peak selected from about 3322 cm−1 and about 2886 cm−1.
The compound of (−) halofenate in a crystalline solid Form A characterized by an X-ray Powder diffraction pattern comprising a peak at about 10.8°2θ and a Raman spectrum comprising at least one peak selected from about 3087 cm−1 and about 1663 cm−1.
Dependencies are inferred from the claim text.